ES2949637T3 - Método de aislamiento y purificación de microvesículas a partir de sobrenadantes de cultivos celulares y fluidos biológicos - Google Patents

Método de aislamiento y purificación de microvesículas a partir de sobrenadantes de cultivos celulares y fluidos biológicos Download PDF

Info

Publication number
ES2949637T3
ES2949637T3 ES19212541T ES19212541T ES2949637T3 ES 2949637 T3 ES2949637 T3 ES 2949637T3 ES 19212541 T ES19212541 T ES 19212541T ES 19212541 T ES19212541 T ES 19212541T ES 2949637 T3 ES2949637 T3 ES 2949637T3
Authority
ES
Spain
Prior art keywords
microvesicles
isolated
cells
present
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19212541T
Other languages
English (en)
Spanish (es)
Inventor
Evangelos V Badiavas
Arsalan Q Shabbir
Stephen C Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Application granted granted Critical
Publication of ES2949637T3 publication Critical patent/ES2949637T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/983—Blood, e.g. plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
ES19212541T 2013-03-13 2014-03-12 Método de aislamiento y purificación de microvesículas a partir de sobrenadantes de cultivos celulares y fluidos biológicos Active ES2949637T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361778591P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
ES2949637T3 true ES2949637T3 (es) 2023-10-02

Family

ID=51625222

Family Applications (2)

Application Number Title Priority Date Filing Date
ES19212541T Active ES2949637T3 (es) 2013-03-13 2014-03-12 Método de aislamiento y purificación de microvesículas a partir de sobrenadantes de cultivos celulares y fluidos biológicos
ES14774189T Active ES2778098T3 (es) 2013-03-13 2014-03-12 Método de aislamiento y purificación de microvesículas de sobrenadantes de cultivo celular y fluidos biológicos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14774189T Active ES2778098T3 (es) 2013-03-13 2014-03-12 Método de aislamiento y purificación de microvesículas de sobrenadantes de cultivo celular y fluidos biológicos

Country Status (13)

Country Link
US (3) US10500231B2 (enExample)
EP (3) EP2972193B1 (enExample)
JP (3) JP6562897B2 (enExample)
CN (2) CN105209881B (enExample)
AU (4) AU2014244618A1 (enExample)
CA (1) CA2906502A1 (enExample)
DK (2) DK2972193T3 (enExample)
ES (2) ES2949637T3 (enExample)
FI (1) FI3677271T3 (enExample)
HU (2) HUE049003T2 (enExample)
PL (2) PL2972193T3 (enExample)
PT (2) PT2972193T (enExample)
WO (1) WO2014159662A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
CN105209881B (zh) * 2013-03-13 2021-01-22 迈阿密大学 从细胞培养上清液和生物流体分离并纯化微泡的方法
US11160904B2 (en) 2017-05-09 2021-11-02 Vivex Biologies Group, Inc. Biological composition in a protectant shroud and methods
US9687511B2 (en) * 2015-03-06 2017-06-27 Vivex Biomedical, Inc. Acellular biologic composition and method of manufacture
US20180325830A1 (en) 2017-05-09 2018-11-15 Vivex Biomedical, Inc. Coated biological composition
JP2018507916A (ja) * 2015-03-11 2018-03-22 ベフファル アタ エクソソーム送達技術
WO2016149358A1 (en) * 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
HRP20230865T1 (hr) * 2015-07-31 2023-11-10 Exotropin, Llc Kompozicije egzosoma i postupci za njihovu pripremu i primjenu za reguliranje i kondicioniranje kože i kose
KR102418785B1 (ko) * 2015-09-25 2022-07-08 (주)프로스테믹스 식물 착즙물 유래 세포 외 소포체를 포함하는 피부 개선 및 탈모 방지용 조성물
KR102475127B1 (ko) * 2015-09-30 2022-12-07 (주)아모레퍼시픽 인삼 유래의 엑소좀 유사 베지클을 포함하는 탈모 방지 또는 육모 촉진용 조성물
WO2017117585A1 (en) * 2015-12-30 2017-07-06 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
US10463695B2 (en) * 2016-01-19 2019-11-05 Matti J. SIRÉN Methods and compositions for use in the prevention, treatment and/or alleviation of cancer
KR102475129B1 (ko) * 2016-03-22 2022-12-07 (주)아모레퍼시픽 인삼 유래의 엑소좀 유사 베지클을 유효성분으로 포함하는 항노화용 조성물
WO2018039100A2 (en) * 2016-08-23 2018-03-01 Albert Einstein College Of Medicine, Inc. Stem cell-produced microvesicles for treating tendon pathologies
EP4364799A3 (en) * 2017-01-11 2024-07-17 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
EP3660142A4 (en) 2017-07-26 2021-05-05 Rosetta Exosome METHOD OF ISOLATION OF EXTRACELLULAR VESICLES USING CATIONS
WO2019023584A1 (en) * 2017-07-27 2019-01-31 Cornell University FIXING AND RETENTION OF EXTRACELLULAR VESICLES
WO2019060719A1 (en) * 2017-09-22 2019-03-28 University Of Miami METHODS AND COMPOSITIONS FOR THE TREATMENT OF BULLETIN EPIDERMOLYSIS
US11471559B2 (en) 2017-11-20 2022-10-18 Vivex Biologics Group, Inc. Bioenergetic bone
EP3735279B1 (en) * 2018-01-29 2025-05-14 Forever Labs, Inc. System and method for isolating extracellular vesicles
CN108414334A (zh) * 2018-02-23 2018-08-17 中山大学附属第医院 一种从精液中分离提纯外泌体的方法
CA3113528A1 (en) 2018-09-21 2020-03-26 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
CA3131922A1 (en) * 2019-02-28 2020-09-03 William Samuel Fagg, Iv Amniotic fluid-derived extracellular vesicles and uses thereof for wound healing
IT201900024580A1 (it) * 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN113384597A (zh) * 2020-03-13 2021-09-14 西比曼生物科技（上海）有限公司 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
CN111893093A (zh) * 2020-08-03 2020-11-06 沈阳三禾生物科技有限公司 一种脐带间充质干细胞来源的超微因子的制备方法
CA3187902A1 (en) 2020-08-21 2022-02-24 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
JPWO2022080461A1 (enExample) * 2020-10-16 2022-04-21
CN114081900B (zh) * 2021-02-24 2024-11-22 济宁医学院附属医院 间充质干细胞来源的纳米微囊泡在制备治疗子痫前期的药物中的应用
CN115212230B (zh) * 2021-04-21 2024-12-27 时比曼生物科技(上海)有限公司 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用
EP4511045A1 (en) 2022-04-19 2025-02-26 University of Miami Compositions comprising microvesicles for use in the prevention and treatment of graft versus host disease
KR20240028586A (ko) * 2022-08-24 2024-03-05 (주) 테라베스트 인간 세포 유래 미세소포체 및 히알루론산 또는 콜라겐을 포함하는 조성물 및 이의 용도
CN116898781B (zh) * 2023-02-07 2025-08-15 中国中医科学院中医基础理论研究所 大麦苗外泌体在制备具有抗衰老修护作用的产品中的应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
CA2225553A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
CO4980885A1 (es) 1997-12-29 2000-11-27 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles en el tratamiento de inflamaciones y metodos para preparar dicho compuesto
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
PT1333833E (pt) 2000-10-23 2011-12-09 Glaxosmithkline Llc Novo composto 8h-pirido[2,3-d]pirimidin-7-ona trissusbtituída para o tratamento de doenças mediadas por csbp/p38 cinase
RU2322497C2 (ru) * 2000-11-30 2008-04-20 Стемрон Инк. Изолированная гомозиготная стволовая клетка (варианты), способ ее получения (варианты), способ получения требуемой клетки-родоначальника, дифференцированной клетки, группы дифференцированных клеток или типа ткани
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
WO2005121369A2 (en) * 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
US20060116321A1 (en) 2004-07-01 2006-06-01 Robbins Paul D Immunosuppressive exosomes
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
CA3061952C (en) 2006-03-09 2022-07-19 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
ES2562607T3 (es) 2006-07-13 2016-03-07 The Ohio State University Research Foundation MIR-21 para el diagnóstico de adenocarcinoma de colon con mal pronóstico de supervivencia
EP1939218A1 (en) * 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
AU2008226974B2 (en) 2007-03-09 2013-08-15 Merck Sharp & Dohme Llc Papillomavirus vaccine compositions
AU2008266014B2 (en) 2007-06-15 2013-06-06 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
WO2009015357A1 (en) 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
US20100255514A1 (en) * 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
ES2409180T3 (es) * 2007-10-15 2013-06-25 Fresenius Medical Care Deutschland Gmbh Uso de microvesículas (MVS), para preparar un medicamento que tiene actividad de adyuvante en el trasplante de células endoteliales, particularmente en el tratamiento de la diabetes mediante el trasplante de islotes pancreáticos,y método relacionado
ES2523098T3 (es) * 2007-10-29 2014-11-20 Fresenius Medical Care Deutschland Gmbh Microvesícula (MV) derivada de células madre para su uso en la inhibición de la apoptosis inducida por un agente citostático
US20110014251A1 (en) 2008-01-04 2011-01-20 Lydac Neuroscience Limited Microvesicles
US8617806B2 (en) 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
US20120058492A1 (en) 2008-01-25 2012-03-08 Hansabiomed Ou Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
KR101970908B1 (ko) * 2008-02-01 2019-04-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
JP5718648B2 (ja) 2008-02-22 2015-05-13 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） 間葉系幹細胞粒子
FR2928926B1 (fr) 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
CN102065870B (zh) * 2008-04-16 2014-11-19 比奥根艾迪克Ma公司 使用聚亚烷基二醇和过渡金属分离生物大分子的方法
US10545149B2 (en) 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
AU2009308152B2 (en) 2008-10-21 2015-05-21 The General Hospital Corporation Cell transplantation
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
BRPI1007321A2 (pt) 2009-01-15 2018-07-10 Laboratory Corp America Holdings métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
JP5658230B2 (ja) 2009-04-13 2015-01-21 インサーム（インスティテュート ナショナル デ ラ セント エ ドゥ ラ ルシェルシュ メディカル） Ｈｐｖ粒子およびその使用
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
BRPI0900815A2 (pt) 2009-04-23 2010-12-28 Sociedade Benef Israelita Bras Hospital Albert Einstein método para isolamento de exossomos a partir de soluções biológicas utilizando nanopartìculas de óxido de ferro
RU2012103482A (ru) 2009-07-02 2013-08-10 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Способ лечения рака, основанный на использовании экзосом
SG2014014617A (en) * 2009-07-16 2014-05-29 Gen Hospital Corp Nucleic acid analysis
DK2521918T3 (en) 2010-01-08 2015-06-29 Cavadis B V DETERMINATION OF EXOSOMAL BIOMARKETS FOR PREVENTION OF CARDIOVASCULAR EVENTS
US20120315324A1 (en) 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
WO2012002760A2 (ko) * 2010-07-01 2012-01-05 포항공과대학교 산학협력단 세균유래 마이크로베시클을 이용한 암치료 및 암진단 방법
JP2013537538A (ja) 2010-08-13 2013-10-03 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ グラスゴー 微小水泡および関連するマイクロｒｎａの治療用途
US20120053976A1 (en) 2010-08-31 2012-03-01 Xerox Corporation System and method for determining whether service costs can be reduced
US20120093885A1 (en) * 2010-10-18 2012-04-19 Northwestern University Therapeutic vesicles
WO2012053976A1 (en) * 2010-10-18 2012-04-26 Agency For Science, Technology And Research Use of exosomes to promote or enhance hair growth
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
WO2012126531A1 (en) 2011-03-24 2012-09-27 Cavadis B.V. Method for diagnosing acute coronary syndrome (acs)
WO2012110099A1 (en) 2011-02-18 2012-08-23 Cavadis B.V. Determination of exosomal biomarkers for predicting cardiovascular events
WO2012110253A2 (en) 2011-02-18 2012-08-23 Cavadis B.V. Exosomal biomarkers for cardiovascular events
WO2012135844A2 (en) 2011-04-01 2012-10-04 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
SG10201603931TA (en) 2011-06-08 2016-07-28 Agency Science Tech & Res Purification Of Biological Products By Constrained Cohydration Chromatography
EP2734543B1 (en) 2011-07-24 2018-10-03 Carmel-Haifa University Economic Corp. Lactoferrin fragments and use thereof
ITRM20110403A1 (it) * 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
US20150018227A1 (en) * 2011-08-05 2015-01-15 University Of Louisville Research Foundation, Inc. Microrna biomarkers
EP2604288A1 (en) 2011-12-16 2013-06-19 Biocant - Associação De Transferência De Tecnologia Nanoparticles and uses thereof
WO2013110253A1 (de) 2011-12-23 2013-08-01 Appbyyou Gmbh Verfahren zum aufbau einer verschlüsselten verbindung zwischen zwei kommunikationsgeräten nach vorherigem schlüsselaustausch über eine kurzstreckenverbindung
US20130273544A1 (en) 2012-04-17 2013-10-17 Life Technologies Corporation Methods and compositions for exosome isolation
WO2013188832A1 (en) 2012-06-14 2013-12-19 System Biosciences, Llc Methods for microvesicle isolation and selective removal
US9005888B2 (en) 2012-06-14 2015-04-14 System Biosciences, Llc Methods for microvesicle isolation and selective removal
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
WO2014028493A2 (en) 2012-08-13 2014-02-20 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
EP3415627A1 (en) 2012-11-13 2018-12-19 Codiak BioSciences, Inc. Delivery of therapeutic agent
US20180104186A1 (en) 2013-03-13 2018-04-19 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
CN105209881B (zh) 2013-03-13 2021-01-22 迈阿密大学 从细胞培养上清液和生物流体分离并纯化微泡的方法
US20160220613A1 (en) 2013-09-16 2016-08-04 Agency For Science, Technology And Research Method
WO2015138878A1 (en) 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
CN107106614A (zh) 2014-09-15 2017-08-29 新加坡科技研究局 用外泌体治疗移植物抗宿主病（gvhd）或大疱性表皮松解症（eb）的方法
WO2016172598A1 (en) 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
MA44699A (fr) 2015-05-29 2021-05-05 Merck Sharp & Dohme Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
US20190133922A1 (en) 2016-01-12 2019-05-09 Kangstem Biotech Co., Ltd. Stem Cell-Derived Exosomes Containing a High Amount of Growth Factors
EP3922253A1 (en) 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
WO2019060719A1 (en) 2017-09-22 2019-03-28 University Of Miami METHODS AND COMPOSITIONS FOR THE TREATMENT OF BULLETIN EPIDERMOLYSIS
CA3187902A1 (en) 2020-08-21 2022-02-24 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells

Also Published As

Publication number Publication date
AU2020223723A1 (en) 2020-09-10
US10500231B2 (en) 2019-12-10
EP4218774A1 (en) 2023-08-02
JP2019195331A (ja) 2019-11-14
CN112795533A (zh) 2021-05-14
AU2018211351C1 (en) 2020-12-10
EP2972193A4 (en) 2016-09-07
US11730768B2 (en) 2023-08-22
JP2022084634A (ja) 2022-06-07
US20160184363A1 (en) 2016-06-30
EP3677271A1 (en) 2020-07-08
PT3677271T (pt) 2023-05-31
US12453745B2 (en) 2025-10-28
PT2972193T (pt) 2020-04-23
CN105209881B (zh) 2021-01-22
HUE062348T2 (hu) 2023-10-28
DK2972193T3 (da) 2020-03-23
JP6562897B2 (ja) 2019-08-21
WO2014159662A1 (en) 2014-10-02
ES2778098T3 (es) 2020-08-07
AU2022206811B2 (en) 2024-08-15
AU2018211351B2 (en) 2020-05-28
US20200163999A1 (en) 2020-05-28
AU2014244618A1 (en) 2015-10-08
DK3677271T3 (da) 2023-05-22
PL3677271T3 (pl) 2023-08-21
CN105209881A (zh) 2015-12-30
HUE049003T2 (hu) 2020-09-28
JP2016518109A (ja) 2016-06-23
US20230364150A1 (en) 2023-11-16
EP2972193B1 (en) 2019-12-18
JP7417301B2 (ja) 2024-01-18
EP2972193A1 (en) 2016-01-20
CA2906502A1 (en) 2014-10-02
JP7405389B2 (ja) 2023-12-26
EP3677271B1 (en) 2023-04-19
FI3677271T3 (fi) 2023-06-06
AU2022206811A1 (en) 2022-08-18
PL2972193T3 (pl) 2020-08-24
AU2018211351A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
ES2949637T3 (es) Método de aislamiento y purificación de microvesículas a partir de sobrenadantes de cultivos celulares y fluidos biológicos
AU2018335788B2 (en) Methods and compositions for the treatment of epidermolysis bullosa
US20180104186A1 (en) Methods and compositions for the treatment of epidermolysis bullosa
CN113717944B (zh) 一种miRNA13896过表达的工程化人脐带间质干细胞源外泌体及制备方法和应用
Wu et al. Urothelial Differentiation of Human Umbilical Cord‐Derived Mesenchymal Stromal Cells In Vitro
Öztürk et al. Immune regulation is more effective in the U937 inflammation model with mesenchymal stem cell extracellular vesicles stimulated by pro-inflammatory cytokines
HK40088378A (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
HK40032447A (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
HK40032447B (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
EA047075B1 (ru) Способы и композиции для лечения буллезного эпидермолиза
CN118909935A (zh) 一种大规模分离外泌体的方法及制备的外泌体和应用